Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	448906-42-1
Formula :	C₁₄H₁₀N₂O₃S
M.W :	286.31
SMILES Code :	O=C(C1=CSC(C(C2=CNC3=C2C=CC=C3)=O)=N1)OC
MDL No. :	MFCD06411597
InChI Key :	KDDXOGDIPZSCTM-UHFFFAOYSA-N
Pubchem ID :	4668801

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

MDA-MB-157 cells	10 μM	3 days	ITE reduced JAG1 protein expression.	Biochem Pharmacol. 2020 Apr;174:113845
MDA-MB-436 cells	10 μM	3 days	ITE reduced JAG1 protein expression.	Biochem Pharmacol. 2020 Apr;174:113845
MCF7 cells	10 μM	3 days	ITE reduced JAG1 protein expression.	Biochem Pharmacol. 2020 Apr;174:113845
BV2 microglia	1 μM	4 hours pretreatment followed by 20 hours co-culture with LPS	To investigate the mechanisms by which ITE protects against retinal ischemia/reperfusion injury through AhR activation. Results showed that ITE pretreatment significantly reduced LPS-induced expression of TNF-α, IL-1β, and iNOS, and this anti-inflammatory effect could be inhibited by AhR antagonist CH223191.	Cell Death Dis. 2023 Feb 8;14(2):92
PBMCs	100 nM ITE, 10 nM IL-11	5 days	To examine the effect of ITE on IL-11-induced differentiation of PBMCs into M-MDSCs. Results showed that ITE alone had a trend of reducing M-MDSCs but did not reach statistical significance; when combined with IL-11, ITE significantly reduced the percentage of M-MDSCs.	Pharmaceuticals (Basel). 2025 Mar 27;18(4):471
GL261 cells	0.1 nM, 10 nM, 10,000 nM	20 hours	To examine the effect of ITE on IL6 and IL11 mRNA and protein levels in GL261 cells. Results showed that ITE significantly down-regulated IL6 and IL11 mRNA levels and IL11 protein levels, but IL6 protein levels remained unchanged.	Pharmaceuticals (Basel). 2025 Mar 27;18(4):471
GL261 cells	0.1 nM, 10 nM, 10,000 nM	20 hours	To examine the effect of ITE on AHR protein levels in GL261 cells. Results showed that ITE treatment slightly increased AHR protein levels in GL261 cells.	Pharmaceuticals (Basel). 2025 Mar 27;18(4):471
MDA-MB-231 cells	10 μM	Days 1, 3 and 5	ITE reduces the expression of JAG1, the amount of Notch 1 intracellular domain (NICD1), and the phosphorylation of STAT3 (at tyrosine 705).	Biochem Pharmacol. 2020 Apr;174:113845
Bone marrow-derived dendritic cells	1 µmol/L	4 hours	ITE inhibited the expression of costimulatory molecules such as CD40, CD80, CD86, and PD-L1 in LPS-induced dendritic cells and promoted the expansion of Foxp3+ regulatory T cells	J Am Heart Assoc. 2021 Jul 6;10(13):e020502
C3A cells	0.2, 0.5, 1 µM	24 and 48 hours	Enhanced the protein levels and metabolic activities of major cytochrome P450 (CYP450) enzymes, including CYP1A1, CYP1A2, CYP3A4, and CYP1B1, and slightly increased albumin secretion and urea synthesis.	Int J Mol Med. 2017 Jan;39(1):101-112
Huh7 cells	0.2, 0.5, 1 µM	24 and 48 hours	Enhanced the protein levels and metabolic activities of major cytochrome P450 (CYP450) enzymes, including CYP1A1, CYP1A2, CYP3A4, and CYP1B1, and slightly increased albumin secretion and urea synthesis.	Int J Mol Med. 2017 Jan;39(1):101-112

C57BL/6J mice	Retinal ischemia/reperfusion injury model	Intraperitoneal injection	10 mg/kg	Once daily until the end of the experiment (day 1, 3, or 7)	To evaluate the protective effects of ITE on retinal ischemia/reperfusion injury. Results showed that ITE treatment significantly alleviated IR-induced retinal ganglion cell (RGC) loss and apoptosis, reduced the expression of retinal local inflammatory factors (TNF-α, IL-1β, and IL6), and these protective effects could be inhibited by AhR antagonist CH223191.	Cell Death Dis. 2023 Feb 8;14(2):92
C57BL/6J wild-type female mice	Orthotopic mouse glioma model	Intraperitoneal injection	100 mg/kg ITE, 80 µg PD1 antibody	ITE every other day, PD1 antibody twice with a three-day interval	To evaluate the effect of ITE combined with PD1 antibody on tumor growth and survival in a mouse glioma model. Results showed that although the tumor growth curve difference did not reach statistical significance, the survival of mice in the ITE+PD1 group was significantly extended. Additionally, the combination therapy significantly reduced MDSCs in the tumor and increased CD8+ T cell infiltration.	Pharmaceuticals (Basel). 2025 Mar 27;18(4):471
C57BL/6J mice	CCl4-induced liver fibrosis model	Intraperitoneal injection	10 mg/kg	Every other day for 4 weeks	To investigate the effect of ITE on CCl4-induced liver fibrosis, results showed that ITE ameliorated liver fibrosis, reducing collagen deposition and fibrogenic gene expression.	Gastroenterology. 2019 Sep;157(3):793-806. e14
C57BL/6 mice	Myocardial infarction model	Intraperitoneal injection	200 µg/mouse	Once daily for 1 week	ITE treatment significantly improved systolic function, reduced infarct size, and increased the number of regulatory T cells and the proportion of M2 macrophages in myocardial infarction mice	J Am Heart Assoc. 2021 Jul 6;10(13):e020502
Mice	Pentobarbital-induced sleep model	Oral	20 mg/kg	Single dose, 45 minutes before pentobarbital injection	Evaluate the effects of ITE on sleep duration and blood melatonin levels. Results showed that ITE significantly increased sleep duration (38.8 ± 4.8 min) and blood melatonin levels (186.0 ± 42.9 pg/mL).	ACS Omega. 2024 Oct 15;9(43):43875-43883

{[proInfo.proName]}

CAS No.: 448906-42-1

{[proInfo.proName]}

CAS No.: 448906-42-1

Product Citations Show More

Alternative Products

Product Details of ITE

Safety of ITE

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00386100	Diabetes Mellitus, Type 2	Phase 4	Completed	-	-
NCT01243424	Diabetes Mellitus, Type 2	Phase 3	Completed	-	-
NCT03108768	Hearing Loss, Bilateral Sensor... More >>ineural, Progressive Less <<	Not Applicable	Completed	-	Switzerland ... More >> Sonova AG Stafa, Zürich, Switzerland, 8712 Less <<
NCT03569228	Hearing Loss	Not Applicable	Not yet recruiting	October 29, 2022	United States, Tennessee ... More >> Mountain Home VA Medical Center James H. Quillen VA Medical Center, Mountain Home, TN Not yet recruiting Mountain Home, Tennessee, United States, 37684 Contact: Sherri L Smith, PhD 423-926-1171 ext 7569 sherri.smith@va.gov Principal Investigator: Sherri L. Smith, PhD Less <<
NCT00386100	-		Completed	-	-
NCT02545569	Hearing Loss, Bilateral or Uni... More >>lateral Less <<	Not Applicable	Not yet recruiting	December 2020	Switzerland ... More >> Sonova AG Recruiting Staefa, Zürich, Switzerland, 8712 Contact: Jana-Kosima Schwarzlos 0041 58 928 0101 JanaKosima.Schwarzlos@sonova.com Less <<
NCT02709486	Osteoarthritis, Hip ... More >> Osteoarthritis, Knee Less <<	Phase 3	Active, not recruiting	December 2018	-
NCT01619345	Diabetes Heal... More >>thy Less <<	Phase 1	Completed	-	United Kingdom ... More >> Nottingham, United Kingdom, NG11 6JS Less <<
NCT02436629	High Intensity Intermittent Sp... More >>orts Performance Less <<	Phase 4	Completed	-	Netherlands ... More >> Maastricht University Medical Centre+ Maastricht, Limburg, Netherlands, 6200MD Less <<
NCT01746992	ALK-negative Anaplastic Large ... More >>Cell Lymphoma Peripherial T Cell Lymphoma,Not Otherwise Specified Angioimmunoblastic T Cell Lymphoma Enteropathy Associated T Cell Lymphoma Hepatosplenic T Cell Lymphoma Subcutaneous Panniculitis Like T Cell Lymphoma Less <<	Phase 4	Active, not recruiting	December 2018	China, Shanghai ... More >> Ruijin hospital Shanghai, Shanghai, China, 200025 Less <<
NCT03596346	Food Safety	Not Applicable	Completed	-	Finland ... More >> Satucon Oy/Pihlajalinna Ite Kuopio, Finland, 70100 Less <<
NCT03770754	Necrosis	Not Applicable	Enrolling by invitation	January 20, 2019	Mexico ... More >> Jorge Paredes Vieyra Tijuana, Baja California, Mexico, 22000 Jorge Paredes Vieyra Tijuana, Baja Califronia, Mexico, 22000 Jose Clemente Orozco Tijuana, BC, Mexico, 22000 Jose Clemente Tijuana, BC, Mexico, 22000 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed